Indications |
Parenteral Anaemia of chronic renal failure Adult: As epoetin alfa: Initially, 50 U/kg SC/IV 3 times wkly for predialysis and haemodialysis patients and 50 U/kg twice wkly for peritoneal dialysis patients, may increase according to response in steps of 25 U/kg 3 times wkly at 4 wkly intervals. Child: As epoetin alfa: Initially, 50 U/kg 3 times wkly. May increase dose at 4 wkly intervals in increments of 25 U/kg 3 times wkly until a target haemoglobin concentration of 9.5-11 g/100 mL is reached. Usual maintenance dose: <10 kg: 225-450 U/kg/wk; 10-30 kg: 180-450 U/kg/wk and >30 kg: 90-300 U/kg/wk. Parenteral Anaemia in zidovudine-treated HIV-infected patients Adult: As epoetin alfa: Initially, 100 U/kg SC/IV thrice wkly for 8 wk; increase every 4-8 wk by 50-100 U/kg according to response. Max: 300 U/kg thrice wkly. Subcutaneous Anaemia related to non-myeloid malignant disease chemotherapy Adult: As epoetin alfa or zeta: Initially, 150 U/kg 3 times wkly. Dose may be increased at 4-8 wk intervals to 300 U/kg 3 times wkly. Stop treatment if response is still inadequate after 4 wk of treatment using this higher dose. Intravenous Increase yield of autologous blood Adult: As epoetin alfa or zeta: 600 U/kg over 2 minutes twice wkly for 3 wk before surgery; in conjunction with iron, folate and B12 supplementation. |
Contraindications |
Uncontrolled hypertension, hypersensitivity to mammalian cell products and human albumin. |
Warnings / Precautions |
Chronic renal failure, ischaemic heart diseases, hypertension, pregnancy, seizures, liver dysfunction, lactation. |
Adverse Reactions |
Hypertension, myalgia, arthralgia, flu-like syndrome, rashes and urticaria. Potentially Fatal: Hypertensive crisis with encephalopathy-like symptoms e.g. headache, confusion, generalised seizures. Thrombosis. |
Drug Interactions |
Haematinics enhance efficiency. Increased dose of heparin in patients undergoing dialysis. See Below for More erythropoietin Drug Interactions |
Mechanism of Actions |
Erythropoietin regulates erythropoiesis by stimulating the differentiation and proliferation of erythroid precursors, stimulating the release of reticulocytes into the circulation, and synthesis of cellular haemoglobin. Recombinant human erythropoietin is available as epoetin alfa and epoetin beta which are used in the management of anaemias associated with CRF, cancer chemotherapy and anti-AIDS drug zidovudine. |
Storage Conditions |
Intravenous: Refrigerate at 2-8°C. Do not freeze. Parenteral: Refrigerate at 2-8°C. Do not freeze. Subcutaneous: Refrigerate at 2-8°C. Do not freeze. |
ATC Classification |
B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. |
Storage |
Intravenous: Refrigerate at 2-8°C. Do not freeze. Parenteral: Refrigerate at 2-8°C. Do not freeze. Subcutaneous: Refrigerate at 2-8°C. Do not freeze. |
Available As |
|
Erythropoietin (Recombinant Human Erythropoietin)
Post Review about Erythropoietin (Recombinant Human Erythropoietin) Click here to cancel reply.
Erythropoietin (Recombinant Human Erythropoietin) Containing Brands
Erythropoietin (Recombinant Human Erythropoietin) is used in following diseases
Drug - Drug Interactions of Erythropoietin (Recombinant Human Erythropoietin)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.